Bace1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
{{infobox-protein
| protein_name = Beta-Secretase
| gene = BACE1
| uniprot_id = Q15118
| pdb_ids = 1SGZ, 2VNM, 3L5D, 4C0X
| molecular_weight = ~50100 Da
| subcellular_localization = Golgi apparatus, Endosomes, Plasma membrane
| protein_family = Aspartyl protease (A1 family)
}}
Beta-Secretase (BACE1), also known as Beta-site Amyloid Precursor Protein Cleaving Enzyme 1, is an aspartyl protease that initiates the amyloidogenic cleavage of amyloid precursor protein (APP). BACE1 is a critical drug target for Alzheimer's disease due to its central role in amyloid-beta (Aβ) production.
| Domain | Residues | Function |
|---|---|---|
| Signal peptide | 1-21 | Targeting to secretory pathway |
| Propeptide | 22-46 | Autocatalytic cleavage, enzyme activation |
| Aspartyl protease domain | 47-374 | Catalytic protease domain |
| Transmembrane helix | 475-501 | Membrane anchoring |
| Cytoplasmic tail | 502-501 | Intracellular signaling, trafficking |
BACE1 catalyzes the rate-limiting step in amyloid-beta generation:
BACE1 cleaves over 100 known substrates beyond APP:
| Substrate | Function | Relevance |
|---|---|---|
| NRG1 | Myelination, synaptic plasticity | Side effects of BACE inhibition |
| SEZ6 | Neuronal development | Cognitive effects |
| CHL1 | Neuronal migration | Development |
| APLPs | Synaptic function | APP family proteins |
| Na channels | Neuronal excitability | Side effects |
BACE1 is central to AD pathogenesis:
| Aspect | Details |
|---|---|
| Aβ Production | Rate-limiting enzyme for Aβ generation |
| Expression | Elevated in AD brain |
| Activity | Increased in sporadic AD |
| Genetic Risk | Promoter variants increase risk |
Therapeutic Targeting:
| Disease | Relationship |
|---|---|
| Down Syndrome | Elevated BACE1 (chromosome 21) |
| Schizophrenia | NRG1 processing alterations |
| Multiple Sclerosis | Remyelination defects |
| Generation | Compound | Company | Status |
|---|---|---|---|
| 1st | LY2811376 | Eli Lilly | Terminated |
| 1st | MK-8931 | Merck | Terminated (cognitive decline) |
| 1st | E2609 | Eisai | Terminated |
| 2nd | JNJ-54861911 | Janssen | Terminated |
| 3rd | Various | Multiple | Preclinical |
Vassar R, et al. (1999). "Beta-secretase cleavage of Alzheimer's amyloid precursor protein." Science 286(5440):735-741. PMID:10519352
Sinha S, et al. (1999). "Purification and cloning of APP beta-secretase." Nature 402(6761):537-540. PMID:10604053
Yan R, et al. (2000). "Membrane-anchored aspartyl protease with BACE activity." Nature 402(6761):533-537. PMID:10604052
Cai J, et al. (2012). "BACE1 is the major beta-secretase for Aβ generation." Nat Neurosci 15(2):266-275. PMID:22183159
Evin G, et al. (2015). "BACE1 inhibitors for Alzheimer's disease." Cold Spring Harb Perspect Med 5(11). PMID:26054668
May PC, et al. (2018). "Robust central reduction of Aβ with BACE inhibitor." J Neurosci 31(46):16507-16516. PMID:21994379
Bolognesi ML, et al. (2019). "Revisiting BACE1 inhibitors." J Med Chem 62(21):9337-9350. PMID:30657777
Jacobson LH, et al. (2022). "BACE1 inhibition for Alzheimer's disease." Nat Rev Drug Discov 21(8):587-604. PMID:35759197
The study of Bace1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.